Address correspondence to: Wolfram Ruf or Thati Madhusudhan, Center for Thrombosis and Hemostasis (CTH), Medical Centre of the Johannes Gutenberg University, Langenbeckstrasse 1, 55131 Mainz, Germany
Quick answer Ozempic uses a multi-dose pen
Dulaglutide and Tirzepatide Litigation British Columbia Class Action On February 11, 2026, Siskinds filed a proposed class action in the Supreme Court of British Columbia, alleging that dulaglutide drugs (Trulicity) and tirzepatide drugs (Mounjaro, Zepbound) manufactured and marketed by the Eli Lilly group of pharmaceutical companies were defective, and that the manufacturers failed to adequately warn users, and their health care providers, that semaglutide drugs increase the risk of serious complications, including gallbladder disorders, severe gastrointestinal injuries (including gastroparesis, or stomach paralysis), blood clots, aspiration during surgery, necrotizing pancreatitis, malnutrition, and vision loss (non-arteritic anterior ischemic optic neuropathy)
professional input
Then the problems appear
The practical implication is that users taking both an anticholinergic medication and a GLP-1 agonist face compounded dry mouth risk